Theravance Biopharma, Inc. and its subsidiaries, along with Mylan, entered into a Settlement Agreement with Mankind Pharma Ltd. and Lifestar Pharma LLC. The agreement resolves patent litigation concerning Theravance and Mylan's YUPELRI (revefenacin) inhalation solution. The litigation was initiated under the Hatch-Waxman Act after Mankind filed an abbreviated new drug application (ANDA) for a generic YUPELRI prior to the expiration of U.S. Patent Nos. 11,484,531, 12,048,692, and 12,285,417. Under the settlement, Mankind is granted a royalty-free, non-exclusive, non-sublicensable, non-transferable license to manufacture and market its generic YUPELRI in the United States. The Licensed Launch Date for Mankind's generic version is set for April 23, 2039, subject to certain exceptions and customary provisions. The settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission. All pending Hatch-Waxman litigation related to YUPELRI (revefenacin) inhalation solution has now been resolved.